Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct

Histopathology

Volumn 62, Issue 3, 2013, Pages 446-457

  Sasaki, Motoko ^a,b   Matsubara, Takashi ^a,b   Yoneda, Norihide ^a,b   Nomoto, Kazuhiro ^a,b   Tsuneyama, Koichi ^a,b   Sato, Yasunori ^a,b   Nakanuma, Yasuni ^a,b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

EZH2; Intraductal papillary neoplasm of the bile duct; Intrahepatic cholangiocarcinoma; MUC mucin core proteins; Polycomb group protein

Indexed keywords

MUCIN 1; MUCIN 6; PROTEIN P53; TRANSCRIPTION FACTOR EZH2;

ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CELL LINE; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; PRIORITY JOURNAL; RNA INTERFERENCE; UPREGULATION;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUCIN-1; MUCIN-6; NEOPLASM INVASIVENESS; POLYCOMB REPRESSIVE COMPLEX 2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84872663559     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12016     Document Type: Article

References (34)

1. Nakanuma Y, Curado M, Fransceschi S et al. Intrahepatic cholagiocarcinoma. In Bosman F, Carneiro F, Hruban H, Theise N eds. World Health Organization classification of tumours of the digestive syste. Lyon: IARC Press, 2010; 217-227.
2. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004; 118; 409-418.
3. Lund AH, van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 2004; 16; 239-246.
4. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397; 164-168.
5. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 2003; 100; 11606-11611.
6. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419; 624-629.
7. Sasaki M, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J. Pathol. 2008; 215; 175-183.
8. Yamaguchi J, Sasaki M, Harada K et al. Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin. Lab. Invest. 2009; 89; 1018-1031.
9. Sasaki M, Nakanuma Y, Kim Y. Characterization of apomicin expression in intrahepatic cholangio-carcinomas and their precursor lesions: an immunohistochemical study. Hepatology 1996; 24; 1074-1078.
10. Zen Y, Sasaki M, Fujii T et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct-an immunohistochemical study of 110 cases of hepatolithiasis. J. Hepatol. 2006; 44; 350-358.
11. Kim YS, Gum JR Jr. Diversity of mucin genes, structure, function, and expression. Gastroenterology 1995; 109; 999-1001.
12. Sasaki M, Ikeda H, Nakanuma Y. Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system: physiological distribution and pathological significance. Prog. Histochem. Cytochem. 2007; 42; 61-110.
13. Shibahara H, Tamada S, Higashi M et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004; 39; 220-229.
14. Aishima S, Kuroda Y, Nishihara Y et al. Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour. Histopathology 2006; 49; 35-44.
15. Ishikawa A, Sasaki M, Ohira S et al. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis. Lab. Invest. 2004; 84; 629-638.
16. Nakanuma Y, Sasaki M. Expression of blood-group-related antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases. Hepatology 1989; 10; 174-178.
17. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev. Biol. 1989; 25; 503-510.
18. Saijyo S, Kudo T, Suzuki M et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J. Exp. Med. 1995; 177; 61-71.
19. Itatsu K, Sasaki M, Yamaguchi J et al. Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am. J. Pathol. 2009; 174; 829-841.
20. Nakahara O, Takamori H, Iwatsuki M et al. Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2. Ann. Surg. Oncol. 2012; 19(Suppl. 3); S565-571.
21. Toll AD, Dasgupta A, Potoczek M et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum. Pathol. 2010; 41; 1205-1209.
22. Chen Y, Xie D, Yin Li W et al. RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett. 2010; 297; 109-116.
23. Shin YJ, Kim JH. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS ONE 2012; 7; e30393.
24. Wang C, Liu X, Chen Z et al. Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma. Mol. Carcinog. 2011; doi: 10.1002/mc.21848. [Epub ahead of print].
25. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 2011; 10; 2497-2503.
26. Nakanuma Y, Sasaki M, Sato Y, Ren X, Ikeda H, Harada K. Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World J. Hepatol. 2009; 1; 35-42.
27. Pietersen AM, Horlings HM, Hauptmann M et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 2008; 10; R109.
28. Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int. J. Oncol. 2011; 38; 345-353.
29. Tsutsumida H, Swanson BJ, Singh PK et al. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin. Cancer Res. 2006; 12; 2976-2987.
30. Xu H, Inagaki Y, Seyama Y et al. Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with beta-catenin in tumor progression. Life Sci. 2011; 88; 1063-1069.
31. Costa NR, Paulo P, Caffrey T, Hollingsworth MA, Santos-Silva F. Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line. PLoS ONE 2011; 6; e26970.
32. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993; 151; 767-776.
33. Li Y, Ren J, Yu W et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J. Biol. Chem. 2001; 276; 35239-35242.
34. Leir SH, Harris A. MUC6 mucin expression inhibits tumor cell invasion. Exp. Cell Res. 2011; 317; 2408-2419.